WO1998005316A1 - Medicaments de lutte contre certaines anomalies de la circulation oculaire - Google Patents
Medicaments de lutte contre certaines anomalies de la circulation oculaire Download PDFInfo
- Publication number
- WO1998005316A1 WO1998005316A1 PCT/JP1997/002629 JP9702629W WO9805316A1 WO 1998005316 A1 WO1998005316 A1 WO 1998005316A1 JP 9702629 W JP9702629 W JP 9702629W WO 9805316 A1 WO9805316 A1 WO 9805316A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retinal
- agent
- diseases
- ocular circulation
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
Definitions
- the present invention relates to an agent for improving ocular circulation disorders. More specifically, the present invention relates to an ocular circulation disorder containing 5-U-hydroxy-2- [2- (2-methoxyphenoxy) ethylamino] ethyl ⁇ -2 monomethylbenzenesulfonamide or an acid addition salt thereof as an active ingredient. Improve the improver. Background art
- eye circulation J There are two main systems of blood circulation in the eye (hereinafter referred to as “eye circulation J”), one of which is circulation through the ciliary artery and the other is circulation through the central retinal artery.
- the ciliary artery passes through arteries such as the choroid, optic papilla, iris, and ciliary body, and blood is drained out of the eye through the smooth artery, while the central retinal artery passes through the optic nerve and the central retinal vein
- the " ⁇ " is divided into arterioles at the optic disc and becomes capillaries.
- examples of circulatory disorders in the ciliary artery system include normal eye ophthalmopathy, retinitis pigmentosa, macular degeneration, optic neuropathy, and iridocyclitis.
- Circulatory disorders of the central retinal artery system include retinal artery occlusion, retinal vein occlusion, glycemic retinopathy, ischemic optic neuropathy, choroidal disease that occurs in retinal lesions, and retinal choroidal disease that involves systemic disease. Disease.
- the above-mentioned diseases caused by the ocular circulation disorder occur when the circulation of the retina, the optic nerve head, the choroid, the iris, the ciliary body, etc. occurs.
- Normal Intraocular Pressure Glaucoma has been gradually identified by recent epidemiological studies as a type of glaucoma that has the highest incidence of intraocular pressure despite its normal range. It is distinguished from ocular EE cataract caused by ocular hypertension, which is referred to as ⁇ cataract.
- Normal intraocular disorders generally have (1) an intraocular pressure including circadian variation of 21 mm Hg or less, (2) an open angle, and (3) glaucomatous optic disc recession.
- Intracranial lesions that can cause optic atrophy It is said that there is no cavity disease and (5) there is no history of massive bleeding or shock [low intraocular disorder and endothelin (ET-1), opthalmology, 43, 554-559, 1999 2 years, and low-eye IH3 ⁇ 4 cataract history and concept, New Ophthalmology, Vol. 8, pp. 493-500, 1999.
- massive bleeding or shock low intraocular disorder and endothelin (ET-1), opthalmology, 43, 554-559, 1999 2 years, and low-eye IH3 ⁇ 4 cataract history and concept, New Ophthalmology, Vol. 8, pp. 493-500, 1999.
- ET-1 may cause retinal choroidal circulation disorders by reducing blood 5S in the optic nerve head. Therefore, it is thought that improving the ocular circulation disorder caused by ET-1 may be one effective treatment method for normal ocular ffli cataract.
- Ocular circulation disorder is the most frequent retinochoroidal disease.
- Retinal choroid diseases caused by ocular circulatory disorders include retinal artery occlusion, retinal vein occlusion, diabetic retinopathy, retinal pigment degeneration, macular degeneration, choroid diseases occurring in retinal lesions, and general diseases.
- Associated retinal choroidal disease The cause of retinal artery occlusion and retinal vein occlusion is unknown, but obstruction of the retinal artery or vein lumen results in impaired retinal circulation and impaired papillary circulation.
- the blood ET-1 level of this patient is high (Clinical Ophthalmology, 46, 431-434, 19).
- Retinitis pigmentosa is a binocular retinopathy that begins as a night-blindness in school age, progressively progresses in visual field impairment and visual impairment and can lead to blindness. This disease is a hereditary disease in which the degeneration of retinal photoreceptors progresses, the retinal choroidal blood vessels become thinner, and circulatory disorders occur. It is said that ocular circulation disorder has also occurred in macular degeneration.
- oral administration of hubericotine (Hubera N: a vitamin E preparation manufactured by Eisai Co., Ltd.) is performed.
- An optic nerve disease associated with optic nerve disorder includes ischemic optic neuropathy and the like. Ischemic optic neuropathy is caused by impaired circulation of optic neurotrophic vessels. Diseases associated with circulatory disorders of the iris include iridocyclitis.
- an object of the present invention is to provide a drug that has no side effects such as toxicity and has an excellent action of improving ocular circulation disorders.
- the present inventors have searched for various compounds in search of a drug that has no side effects such as toxicity and has an excellent ocular circulation disorder improving action.
- the present inventors have concluded that 5-U-hydroxy-2-C2- (2-methoxyphenoxy) ethylamino] ethyl ⁇ -12-methylbenzene which is an active ingredient of the agent for improving ocular circulation disorder of the present invention.
- Sulfonamide hereinafter, "amoslorol j or its hydrochloride is sometimes referred to as" amoslorol hydrochloride J ". Including these two," the compound J of the present invention is sometimes referred to collectively.
- the present inventors have found that they have an unexpectedly excellent effect on improving ocular circulatory disorders and have completed the present invention.
- Japanese Patent Application Laid-Open No. 55-73610 merely describes the compound of the present invention in the same manner as in the above-mentioned publication. Furthermore, the present applicants have found that the compound of the present invention has an intraocular pressure lowering effect, and based on this finding, filed a patent application for the use of the compound for treating cataract. (PCT / JP93 / 0654, WO93 / 24121).
- the present invention provides a formula
- the acid addition salts include inorganic acid salts such as hydrochloride and sulfate, and organic acid salts such as maleate, tartrate, and citrate, and hydrochloride (ie, amoslurol hydrochloride). It is good.
- the agent for improving ocular circulation disorder of the present invention has an excellent effect of improving ocular circulation disorder and has no side effects such as toxicity, so that normal tension glaucoma and retinal artery occlusion , Retinal vein occlusion, diabetic retinopathy, retinitis pigmentosa, macular degeneration, choroidal disease occurring in retinal lesions, retinal choroidal disease associated with systemic disease, ischemic visual neurosis, iridocyclitis, etc. It can be used as a safe drug for the prevention and treatment of various diseases caused by ocular circulation disorders.
- amosulalol or an acid addition salt thereof When used as an agent for improving ocular circulation disorder, it is usually mixed with a known pharmacologically acceptable carrier, excipient, diluent, etc., and in accordance with a known method, for example, eye drops , Ophthalmic solution, parenteral formulation such as ophthalmic solution, injection, or as an oral formulation such as tablets, capsules, granules, etc. Preferably, it is used.
- a buffer for example, when the agent for improving ocular circulation disorder of the present invention is used as an eye drop, a buffer, a tonicity agent, a preservative, a solubilizing agent, and the like which are usually blended in the eye drop unless the purpose of the present invention is impaired.
- Stabilizers and additives such as a pH adjuster, a thickener, and a chelating agent may be added as appropriate.
- examples of the buffer include a phosphate buffer, a borate buffer, a citrate buffer, a tartrate buffer, an acetate buffer, an amino acid, and the like, such as sodium acetate. It is preferred to use the acetate salt of
- tonicity agent examples include sugars such as sorbitol, glucose, and mannitol; polyhydric alcohols such as glycerin, polyethylene glycol, and propylene glycol; and salts such as sodium chloride, and glycerin is preferably used.
- benzalkonium chloride for example, benzalkonium chloride, benzethonium chloride, para-hydroxybenzoic acid esters such as methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate, benzyl alcohol, phenethyl alcohol, sorbic acid or a salt thereof, thimerosal, chloroform
- benzalkonium chloride para-hydroxybenzoic acid esters such as methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate, benzyl alcohol, phenethyl alcohol, sorbic acid or a salt thereof, thimerosal, chloroform
- examples thereof include butanol, and the use of benzalkonium chloride is preferred.
- solubilizers examples include cyclodextrins and derivatives thereof, water-soluble polymers such as polyvinyl vilolidone, and surfactants.
- solubilizers include cyclodextrins and derivatives thereof, water-soluble polymers such as polyvinyl vilolidone, and surfactants.
- Polyvinyl pyrrolidone ⁇ cyclodextrin is preferred. preferable.
- pH adjusting agent examples include hydrochloric acid, acetic acid, phosphoric acid, sodium hydroxide, and hydrating hydroxide, and it is preferable to use hydrochloric acid.
- thickener examples include hydroxyethyl cellulose, hydroxybutyl pill cellulose, methylcellulose, and ⁇ -xybutyl pillmethylcellulose, and carbohydrate.
- Xymethylcellulose and its salts examples include hydroxyethyl cellulose, hydroxybutyl pill cellulose, methylcellulose, and ⁇ -xybutyl pillmethylcellulose, and carbohydrate.
- Examples of the chelating agent include sodium edetate, sodium citrate, and condensed sodium phosphate.
- purified ocular base such as purified lanolin, petrolatum, blasti base, liquid paraffin, polyethylene glycol and the like are appropriately used.
- the agent for improving ocular circulation disorder of the present invention can be used as an oral preparation such as tablets, capsules, granules and the like, or as an injection.
- the dose of the agent for improving ocular circulation disorder of the present invention varies depending on the administration route, symptoms, age and weight of the patient. For example, when used as an ophthalmic solution in adult patients with normal tension glaucoma, an active ingredient is required.
- the mothralol or its acid addition salt is about 0.001-5. ⁇ Preferably about. It is desirable to administer 1 to several drops of S 1 to several times a day 2 to 6 times a day as an aqueous ophthalmic solution containing about 0.5 to 1.
- the active ingredient is contained in an amount of about 0.001 to 10% w / w%, preferably 0.05% to 0% w / w%. It is desirable to administer about 2 to 6 times a day as an eye softener containing a certain amount depending on the symptoms.
- one or more other agents for improving ocular circulation disorder may be appropriately added as long as the object of the present invention is not adversely affected.
- the agent for improving ocular circulation disorder of the present invention may appropriately contain a component having another medicinal effect in addition to the above agent for improving ocular circulation disorder, as long as the object of the present invention is not contravened.
- the present invention will be described in more detail with reference to Examples, and the effects of the present invention will be clarified by Test Examples. However, these are merely examples, and the scope of the present invention is limited by these. is not.
- An aqueous ophthalmic solution was prepared according to the following formulation.
- An aqueous ophthalmic solution was prepared according to the following formulation.
- An aqueous ophthalmic solution was prepared according to the following formulation.
- An aqueous ophthalmic solution was prepared according to the following formulation.
- Amoslarol hydrochloride 0.5 g Concentrated glycerin 2.6 g Sodium acetate 0.1 Polyvinylpyrrolidone 0.5 g Benzalkonium chloride 0.005 g Dilute hydrochloric acid qs
- An aqueous ophthalmic solution was prepared with the following formulation
- Amosulalol hydrochloride 1.0 g Concentrated glycerin 2.6 g Sodium monohydrogen phosphate 0.1 g Polyvinyl bicarbonate 1.0 g Sodium edetate 0.055 g Benzalkonium chloride 0.005 g Sodium hydroxide (pH 4.0) Add sterile purified water to make a total volume of 100 ml ⁇
- An aqueous ophthalmic solution was prepared according to the following formulation.
- Amosulalol hydrochloride 0.5 g concentrated glycerin 0.1 S sodium acetate 2.6 g polyvinylpyrrolidone 0.1 g benzalkonium chloride 0.005 g diluted hydrochloric acid qs
- An eye ointment was prepared according to the following formulation.
- An eye softener was prepared according to the following formulation.
- Amosulalol hydrochloride 0.5 g Liquid paraffin 1.0 g White petrolatum qs
- Colored male datsushi rabbits weighing about 2 kg were purchased from the Fukusaki Rabbit Union and used after confirming that there were no abnormalities in the eyes. The breeding is performed at a temperature of 23 ⁇ 3 and a humidity of 55 ⁇ 10%, and a solid feed (Lab R Stock, manufactured by Nippon Agricultural Industry Co., Ltd.) is given 100 g / day, and tap water is freely available. Was.
- the agent for improving ocular circulation disorder of the present invention containing 0.5% (w / v) of amosuralol hydrochloride obtained in Example 7 was used.
- a physiological saline solution was used as a control.
- Microsyringe to both eyes of the rabbit was dilated (Hamilton Co., 25 1) have use the observation products et fundus in Vito Rectifiers Tommy lens (manufactured by Sun Contact Lens Co.), 10- ⁇ ⁇ , ⁇ -1 (human, manufactured by SI GMA) was administered in the center of the vitreous body.
- Blood flow was measured 30 minutes before administration of ⁇ -1 and 2 hours after administration at 30-minute intervals after administration. The initial value of the blood flow was measured at 15-minute intervals and averaged over two stable values.
- test drug 60 minutes before and 30 minutes before administration of ⁇ -1, and immediately before and 60 minutes after administration, the test drug was instilled into one eye and the opposite eye was instilled with physiological saline in the same manner.
- FIG. 1 is a graph showing the relative optic disc blood flow (the blood flow at each time point when the initial value is 100%) of the control eye and the eye drops of the test drug.
- the horizontal axis represents the time (minutes) when ET-1 infusion was set to 0, and the vertical axis represents the relative optic nerve-L head blood flow (%).
- Each value represents the average soil standard error (the number of cases is 6).
- the closed circles show the results when the amosulalol ophthalmic solution of Example 7 (test drug) was applied, and the open circles show the case when the physiological saline solution (control) was applied.
- control eyes a significant decrease in blood flow was observed from 30 minutes to 120 minutes after intravitreal injection of ET-1 and a maximum of 36.3% at 90 minutes after ET-1 injection. was seen.
- the eye drops of the test drug did not show any decrease in blood flow as in the control eyes, and significantly reduced the decrease in blood flow from 30 minutes to 120 minutes after administration of ET-1.
- amosularol hydrochloride is a clinically useful drug for ocular circulation disorders.
- amoslalol hydrochloride has the effect of suppressing the decrease in blood flow in the optic nerve head induced by injecting ET-1. Therefore, normal tension glaucoma and retina Retinitis associated with pigmentary degeneration, macular degeneration, ischemic optic neuropathy, iridocyclitis, retinal artery occlusion, retinal vein occlusion, diabetic retinopathy, retinal lesions, and systemic diseases It is useful for the prevention and treatment of various diseases caused by ocular circulation disorders such as choroidal diseases.
- WO93 / 241121 discloses that the acute toxicity (LD 60 when administered orally and intravenously) of amothralol hydrochloride in mice is very low, 5 Preparation of the present invention (an ophthalmic solution containing 0.5% of amosularol hydrochloride) and an aqueous ophthalmic solution containing 0.1% of amosuralol hydrochloride in the same formulation as those of the present invention, even when administered to a heron for 28 days by continuous eye drops It states that no ocular local toxicity such as irritation was observed. Therefore, amoslorol hydrochloride is a very clinically safe drug. Industrial applicability
- the agent for improving ocular circulation disorder of the present invention has an excellent ocular circulation disorder improving effect, particularly in the case of eye drops, and has no side effects such as toxicity. Therefore, normal intraocular pressure disorder, retinitis pigmentosa, macular degeneration, Ocular circulatory disorders such as hematologic optic neuropathy, iridocyclitis, retinal artery occlusion, retinal vein occlusion, diabetic retinopathy, choroidal disease that occurs with retinal disease, and retinal choroidal disease with systemic disease Can be safely used as a preventive / therapeutic agent for various diseases
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97933066A EP0955045A4 (en) | 1996-08-02 | 1997-07-25 | DRUGS TO FIGHT CERTAIN ANOMALIES OF EYE CIRCULATION |
CA002262987A CA2262987A1 (en) | 1996-08-02 | 1997-07-25 | Anti-ocular circulatory disturbance composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22056296 | 1996-08-02 | ||
JP8/220562 | 1996-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998005316A1 true WO1998005316A1 (fr) | 1998-02-12 |
Family
ID=16752943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/002629 WO1998005316A1 (fr) | 1996-08-02 | 1997-07-25 | Medicaments de lutte contre certaines anomalies de la circulation oculaire |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0955045A4 (ja) |
KR (1) | KR20000016784A (ja) |
CN (1) | CN1226161A (ja) |
CA (1) | CA2262987A1 (ja) |
ID (1) | ID19891A (ja) |
WO (1) | WO1998005316A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024121A1 (en) * | 1992-05-22 | 1993-12-09 | Senju Pharmaceutical Co., Ltd. | Remedy for glaucoma |
WO1994001096A1 (en) * | 1992-07-02 | 1994-01-20 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511024A (ja) * | 1993-06-08 | 1996-11-19 | バイディ ファーマシューティカルズ | 眼内圧を低下させる方法および組成物 |
-
1997
- 1997-07-23 ID IDP972552A patent/ID19891A/id unknown
- 1997-07-25 CN CN97196788A patent/CN1226161A/zh active Pending
- 1997-07-25 EP EP97933066A patent/EP0955045A4/en not_active Withdrawn
- 1997-07-25 WO PCT/JP1997/002629 patent/WO1998005316A1/ja not_active Application Discontinuation
- 1997-07-25 CA CA002262987A patent/CA2262987A1/en not_active Abandoned
- 1997-07-25 KR KR1019980710394A patent/KR20000016784A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024121A1 (en) * | 1992-05-22 | 1993-12-09 | Senju Pharmaceutical Co., Ltd. | Remedy for glaucoma |
WO1994001096A1 (en) * | 1992-07-02 | 1994-01-20 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
Non-Patent Citations (2)
Title |
---|
ACTA SOCIETATIS OPHTHALMOLOGICAE JAPONICAE, Vol. 100, No. 4, (April 1996), TORU TANIGUCHI et al., "The Influence of Amosulalol Hydrochloride on Rabbit Ocular Tension and Aqueous Humor Kinetics (in Japanese)", pages 279-283; & DATABASE MEDLINE ON STN, US NATIONAL LIBRARY OF MEDICINE, (BETHESDA, MD, USA), No. * |
See also references of EP0955045A4 * |
Also Published As
Publication number | Publication date |
---|---|
CA2262987A1 (en) | 1998-02-12 |
CN1226161A (zh) | 1999-08-18 |
EP0955045A4 (en) | 2000-11-15 |
KR20000016784A (ko) | 2000-03-25 |
EP0955045A1 (en) | 1999-11-10 |
ID19891A (id) | 1998-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993024121A1 (en) | Remedy for glaucoma | |
KR20240052865A (ko) | 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법 | |
WO2003018057A1 (fr) | Remede contre le glaucome contenant en tant qu'ingredient actif un compose presentant un effet inhibiteur de la kinase pi3 | |
US7638516B2 (en) | Agent for therapeutic treatment of optic nerve diseases and the like | |
JP5363123B2 (ja) | 網膜神経又は視神経の保護剤 | |
US20100137342A1 (en) | Methods for treating vascular disruption disorders | |
HU213272B (en) | Process for producing pharmaceutical composition containing sorbitol for topical treating enhanced intraocular tension | |
JP4828670B2 (ja) | 眼循環障害改善剤 | |
US5519030A (en) | Method for prophylaxis and treatment of myopia | |
US20040013729A1 (en) | Single-drop multiple-agent composition for topical delivery to the eye | |
WO1998005316A1 (fr) | Medicaments de lutte contre certaines anomalies de la circulation oculaire | |
TW304879B (ja) | ||
WO1998029135A1 (en) | Drugs for ameliorating ophthalmic circulatory disturbance | |
JPH10316571A (ja) | 眼循環障害改善剤 | |
Moore | 8 Chapter Anticholinergic Agents (Parasympatholytics) | |
JPWO2002051431A1 (ja) | 網膜虚血に基づく疾患の治療および/または予防剤 | |
Ochoa-Araujo | A Trabecular Micro-Bypass Stent Combined with Phacoemulsification Efficiently Reduces Intraocular Pressure in Primary Open Angle Glaucoma in Mexican Population | |
JP2741285B2 (ja) | 緑内障治療剤 | |
JP2004250347A (ja) | 網膜虚血に基づく疾患の治療および/又は予防剤 | |
EP2632449B1 (en) | Treatment of ocular and cerebral ischemia | |
WO1999018970A1 (fr) | Medicaments a action preventive et remedes contre les troubles circulatoires ophtalmiques | |
Polak | Drugs used in ocular treatment | |
WO2007097205A1 (ja) | 点眼剤 | |
WO2010035768A1 (ja) | ポリアルキレングリコールを有効成分として含有する網膜疾患の予防又は治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97196788.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN HU JP KR RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1019980710394 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09230072 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997933066 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2262987 Country of ref document: CA Ref document number: 2262987 Country of ref document: CA Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1997933066 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980710394 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997933066 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980710394 Country of ref document: KR |